June 27, 2006 / Research Triangle Park, NC — Clinipace, Inc., a software company focused on late-stage clinical research studies and registries today announced its newest academic research center client – the Antiphospholipid Syndrome Collaborative Registry (APSCORE) managed by investigators at the Thurston Arthritis Research Center in the School of Medicine at the University of North Carolina at Chapel Hill. APSCORE selected Clinipace’s clinical research software – called Tempo® – to collect and update clinical, demographic and laboratory data on patients with Antiphospholipid Syndrome (APS) nationwide.
Using in-house technology, APSCORE built a substantial registry database from data collected at eight academic medical centers over the past four years. When the existing technology was retired, APSCORE chose Clinipace’s Tempo as a replacement based on Tempo’s robust clinical workflow support, ease of use, and its ability to seamlessly import four years of legacy data. Clinipace also received the recommendation of researchers running another UNC-based registry using Tempo – the North Carolina Collaborative Stroke Registry.
According to APSCORE study coordinator, Gail Buxton, APSCORE wanted the new system logically laid out and to reduce the overall burden on researchers at the sites. “Tempo’s forms are simply organized in a straightforward way – there’s no scrolling through pages to find the next appropriate question because the system has built-in skip logic. Plus, the workflows are configured to correspond with the natural data flow making the data entry process very smooth and straightforward.”
APSCORE has further reduced the burden at the site by leveraging Tempo’s verification feature that asks the user to verify the entered data. Buxton explains, “When you’re entering large amounts of data for hundreds of patients, simple human errors are bound to creep in, but with Tempo, there’s a confirmation page naturally within the workflow that asks the user to confirm the data values. This not only reduces the amount and frequency of data-input errors, but also reduces the burden on a site by substantially decreasing time spent going back and correcting mistakes.”
Not only were APSCORE personnel looking for a simple yet robust solution, but they also needed to seamlessly extract, transform and load four years of legacy data into the new system. Clinipace achieved this through its proprietary java-based ETL tool that extracts, converts, and loads data from legacy applications into the Tempo platform. “We designed this tool in anticipation of the industry’s need to integrate data from various sources, to convert traditional paper registries into electronic registries, to create an upgrade path for registries built on older technology and to rescue studies that are in trouble,” commented Chris Porter, Vice President of Operations at Clinipace. “We are very pleased to be able to respond to the unique needs of this registry.”
“Clinipace has proven to be a committed and capable partner, and we believe they are one of the few firms that could handle the legacy data issue and the overall complexity of converting a live registry to the Tempo system,” added Dr. Robert Roubey, Associate Professor of Medicine at UNC Chapel Hill School of Medicine, and the APSCORE principal investigator.
Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace, please visit: www.clinipace.com
The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Center on Minority Health and Health Disparities (NCMHD). The purpose of this national registry is to collect and update clinical, demographic, and laboratory data on patients with Antiphospholipid Syndrome (APS), as well as patients with antiphospholipid antibodies who do not have other symptoms commonly associated with APS. The registry also serves as a repository of blood samples from those enrolled in the registry.
The registry is designed as a multi-center, multi-specialty, collaborative project involving a group of leading APS physicians at 8 academic medical centers. The registry’s coordinating center is housed in the Thurston Arthritis Research Center in the School of Medicine at the University of North Carolina at Chapel Hill. For more information on APSCORE, please visit: www.apscore.org.